Adicet Bio

Intangible assets: Adicet owns a differentiated allogeneic gamma delta T‑cell platform, multiple fast track designations for prula‑cel (LN, refractory SLE with extrarenal involvement, and systemic sclerosis), a CRISPR collaboration with an opt‑in right for a 50/50 cost/profit split on certain gene‑edited programs, and a binder/armoring toolkit (e.g., IL‑12 armoring; MED12 knockout) for ADI‑212. These provide scientific differentiation but remain unproven as scalable competitive barriers until pivotal‑quality data and manufacturing reliability are demonstrated.

Switching costs: if prula‑cel induces durable drug‑free remission with acceptable safety, switching costs could be high for patients and physicians. Today, evidence is preliminary and non‑comparative, so switching costs are only potential. Network effects: none.

Cost advantage: allogeneic, off‑the‑shelf supply plus FDA‑permitted outpatient dosing could reduce cost and complexity vs. autologous CAR‑T if efficacy holds, but manufacturing scale‑up and release testing are non‑trivial, so advantages are still hypothetical.

Efficient scale: autoimmune cell therapy is likely to become crowded, and no capacity bottleneck or protected territory exists yet. Overall, the moat is nascent and contingent on future trial outcomes and scale economics.